Cargando…

Acute myeloid leukemia with hepatic infiltration presenting as obstructive jaundice

We present the case of a 55-year-old woman who presented with laboratory studies concerning for acute myeloid leukemia (AML) as well as obstructive cholestasis. In similar previously reported cases, concerns of chemotherapy toxicity exacerbated by liver dysfunction or concerns of untreated, concurre...

Descripción completa

Detalles Bibliográficos
Autores principales: Walsh, Landis R., Yuan, Chaofan, Boothe, James T., Conway, Heather E., Mindiola-Romero, Andres E., Barrett-Campbell, Odeth O., Yerrabothala, Swaroopa, Lansigan, Frederick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184649/
https://www.ncbi.nlm.nih.gov/pubmed/34141563
http://dx.doi.org/10.1016/j.lrr.2021.100251
Descripción
Sumario:We present the case of a 55-year-old woman who presented with laboratory studies concerning for acute myeloid leukemia (AML) as well as obstructive cholestasis. In similar previously reported cases, concerns of chemotherapy toxicity exacerbated by liver dysfunction or concerns of untreated, concurrent cholecystitis in a neutropenic patient often delay initiation of chemotherapy for full medical workup. At admission, our patient was started on the cytoreductive agent hydroxyurea. By day 10 of her medical workup, her liver function had improved with total bilirubin levels normalizing. At that time, full-dose 7 + 3 induction with cytarabine and daunorubicin was then initiated.